Axonics, Inc. (Nasdaq: AXNX) has announced that it has entered into a definitive agreement to be acquired by Boston Scientific Corporation (NYSE: BSX) for US$71 in cash per share, representing an equity value of approximately US$3.7 billion.
Latham & Watkins LLP represented J.P. Morgan Securities LLC, as financial advisor to Axonics, in the transaction with a corporate deal team led by New York/Orange County partner Charles Ruck and Bay Area partner Luke Bergstrom, with associate Eric Czubiak.
